Nina Cosdon

Listen to our interview with Sanofi vaccine expert Dr. Christopher Rizzo about what this preferential recommendation means, and why high-dose flu vaccines are needed for older adults.

Women who were taking hormone replacement therapy (HRT) for at least 6 months before COVID-19 infection had a 22% reduced risk of mortality.

Wearable health sensors predicted COVID-19 infection with up to 73% accuracy 2-10 days before symptom onset.

The largest genome sequence of S Typhi found strains of the bacteria are developing and spreading resistance to new antibiotics.

Eric Shaff, president and CEO of Seres Therapeutics, discusses the confirmatory trial findings for SER-109. Seres is filing a Biologics License Application for the recurrent C diff therapy.

Using confirmed monkeypox cases in the Netherlands, investigators estimated the average time from infection to symptom onset was 8.5 days.

Following VRBPAC recommendations earlier this week, both the Pfizer-BioNTech and Moderna COVID-19 vaccines were FDA-authorized for children as young as 6 months.

Out of 102 monoclonal antibodies tested, only Cv2.1169 and Cv2.3194 cross-neutralized all variants of concern, including Omicron BA.1 and BA.2 subvariants.

Today, the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted to recommend both the Moderna and Pfizer-BioNTech COVID-19 vaccines for children as young as 6 months old.

Green Pharmaceuticals Inc. issued a voluntary recall of their SnoreStop NasoSpray after FDA testing found the product contaminated with the microbe Providencia rettgeri.

The CDC recently compiled surveillance data showing the span and prevalence of 7 major pathogens commonly carried by blacklegged ticks.

Sanofi and GSK’s booster vaccine candidate is modeled on the Beta COVID-19 variant, and increases Omicron-neutralizing antibody titers 40-fold.

Joined by Steven Wolfe, DO, MPH, and Stuart A Fisk, CRNP, of the Allegheny Health Network, we discuss the populations most at risk of HIV infection, as well as advice for making healthcare spaces more inclusive and accessible for LGBTQ+ people.

AstraZeneca’s Evusheld, dual injections of tixagevimab and cilgavimab, reduced the risk of severe or fatal COVID-19 disease by 50%. When administered within 3 days of symptom onset, Evusheld had an 88% risk reduction.

SER-109, the investigational oral microbiome therapeutic from Seres, reduced C diff recurrence by 91.3% in at-risk populations.

Moderna’s bivalent COVID-19 vaccine booster, mRNA-1273.214, generated nearly twice the protective antibodies against Omicron.

Impairment of cognitive function is a growing, concerning effect of "long COVID."

Adults living with HIV were more likely to have a breakthrough COVID-19 infection after vaccination, suggesting a need for additional vaccine doses in this population.

There are now over 25 monkeypox infections confirmed in 12 US states and DC. There are an estimated 900 cases worldwide.

COVID-19 mortality is most frequent in men 60-77 years old with acute lung injury.

In 2020, COVID-19 mortality rates were 5 times higher among adults in low socioeconomic positions.

The FDA and other health agencies are investigating fresh organic strawberries, branded as FreshKampo or HEB, that are believed to be the source of hepatitis A infections in the US and Canada.

At a media briefing this morning, Infectious Diseases Society of America (IDSA) experts discussed the worldwide 600 confirmed cases of monkeypox.

Synairgen's inhalable Interferon-beta treatment, SNG001, may be a treatment option for hospitalized and immunocompromised COVID-19 patients.

The investigational, fully human IgG1 monoclonal antibody ADG20 prevented and treated infection with COVID-19 variants of concern.

There are approximately 300 reported cases of monkeypox in about a dozen countries. However, Dr. Peter Hotez believes we are well equipped to prevent and treat the viral infection.

Verrica received a Complete Response Letter from the FDA regarding their New Drug Application for the topical molluscum contagiosum treatment, VP-102.

RBX2660, an investigational microbiota-based live biotherapeutic for the treatment of C difficile, safely and effectively reduced recurrent C diff for 6 months.

Seres Therapeutics shared phase 3 trial results demonstrating their investigational microbiome-based therapeutic, SER-109, prevented recurrent C difficile infection (rCDI) in 88% of recipients.